Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Mersana Therapeutics Inc (NASDAQ: MRSN) was $0.67 for the day, down -4.96% from the previous closing price of $0.70. In other words, the price has decreased by -$4.96 from its previous closing price. On the day, 2.79 million shares were traded. MRSN stock price reached its highest trading level at $0.7018 during the session, while it also had its lowest trading level at $0.6484.
Ratios:
Our analysis of MRSN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.35. In the meantime, Its Debt-to-Equity ratio is 30.00 whereas as Long-Term Debt/Eq ratio is at 15.51.
JP Morgan Upgraded its Underweight to Neutral on March 19, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 16 ’25 when Mandelia Ashish sold 3,554 shares for $0.58 per share. The transaction valued at 2,061 led to the insider holds 57,519 shares of the business.
Protopapas Anna sold 8,637 shares of MRSN for $5,009 on Jan 16 ’25. The Director now owns 168,041 shares after completing the transaction at $0.58 per share. On Jan 16 ’25, another insider, Lowinger Timothy B, who serves as the SVP, Chief Sci.&Tech. Officer of the company, sold 8,048 shares for $0.58 each. As a result, the insider received 4,668 and left with 257,673 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRSN now has a Market Capitalization of 82186504. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.36 while its Price-to-Book (P/B) ratio in mrq is 77.90.
Stock Price History:
The Beta on a monthly basis for MRSN is 1.62, which has changed by -0.81530344 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, MRSN has reached a high of $6.28, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is -50.46%, while the 200-Day Moving Average is calculated to be -65.00%.
Shares Statistics:
MRSN traded an average of 4.58M shares per day over the past three months and 5189350 shares per day over the past ten days. A total of 122.87M shares are outstanding, with a floating share count of 86.42M. Insiders hold about 30.04% of the company’s shares, while institutions hold 59.94% stake in the company. Shares short for MRSN as of 1738281600 were 9466402 with a Short Ratio of 2.17, compared to 1735603200 on 8849970. Therefore, it implies a Short% of Shares Outstanding of 9466402 and a Short% of Float of 10.05.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.14 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.55 and -$0.68 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.74, with 6.0 analysts recommending between -$0.5 and -$0.91.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $12.6M to a low estimate of $1M. As of the current estimate, Mersana Therapeutics Inc’s year-ago sales were $10.7M
A total of 11 analysts have provided revenue estimates for MRSN’s current fiscal year. The highest revenue estimate was $36.73M, while the lowest revenue estimate was $24M, resulting in an average revenue estimate of $31.04M. In the same quarter a year ago, actual revenue was $36.85M
